JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil
Recruiting
N/A
Interventional Study
Androgenetic Alopecia
Androgenic Alopecia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 50
- Sex
- Male
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 25 (estimated)
- Sponsor
- Kasr El Aini Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy. Clinical response w…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Male adults aged 18 to 50 years with androgenetic alopecia.
* Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V.
* Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month.
* …
Contacts